**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Álvaro Gragera Martínez, Unidad Multidisciplinar de Amiloidosis por TTR, Juan Ramon Jimenez University Hospital, Huelva, Spain

**Main Body of the Abstract**
Currently, ATTRv requires diagnosis and clinical follow-up. Light chain Neurofilaments (NfL) are a diagnostic tool in pathologies with axonal damage, such as polyneuropathy. ATTRv can be followed by quantifying NfL, allowing detect changes earlier than in electrophysiological tests and before clinical symptoms are established. The prognosis and quality of life, thanks to new drugs that stop disease progression, have improved significantly quality of life, as long as it is started as soon as possible. Determining NfL in carriers and patients allows us to know if there is disease activity as earlier as possible.
NfL measurement is not available in most Spanish hospitals.
CENTTINELLA program, which allows measure NfL levels, to be universalized to any Spanish hospital.
Determination of NfL for the diagnosis and follow-up of patients and carriers of ATTRv.
Protocol for collecting samples and sending them to the reference hospital, with a response time of 15 days, facilitating clinical decisions.
In the first 6 months of the program, 150 applications have been received from 12 different provinces in the country.
NfL should be universalized for diagnosis and follow-up of ATTRv. We propose the creation of more programs that allow its use.
Based on our experience, we propose its use for monitoring carriers, detecting increases in NfL levels to initiate early treatment. Monitoring of patients undergoing treatment, drug change in the event of therapeutic failure. In patients with liver transplant clinically stable, demonstrate disease progression.
Include NfL levels in clinical guidelines to establish change from carriers to patients.



CENTINNELA program: access to use of Neurofilament Light Chain for diagnosis al follow-up of patients and carriers with ATTRv PB35 (#289)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.